Search Results for "rituximab"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rituximab. Results 21 to 22 of 22 total matches.
See also: Rituxan
In Brief: Tafasitamab (Monjuvi) for Diffuse Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
's lymphoma. Standard first-line
treatment of DLBCL consists of the combination
of rituximab ...
Tafasitamab-cxix (Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated
approval from the FDA for use in combination with
lenalidomide (Revlimid) for treatment of relapsed or
refractory diffuse large B-cell lymphoma (DLBCL),
not otherwise specified, including DLBCL arising from
low grade lymphoma, in adults who are not eligible
for autologous stem cell transplant. Accelerated
approval was based on overall response rates.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e133 doi:10.58347/tml.2023.1682d | Show Introduction Hide Introduction
Seladelpar (Livdelzi) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
, and rituximab have also been tried, but
their benefits are unclear.
Obeticholic acid (Ocaliva), a farnesoid X ...
Seladelpar (Livdelzi – Gilead), a peroxisome
proliferator-activated receptor (PPAR)-delta agonist,
has received accelerated approval from the FDA for use
in combination with ursodeoxycholic acid (ursodiol,
UDCA; Urso Forte, and generics) for treatment of
primary biliary cholangitis (PBC) in adults who had an
inadequate response to UDCA and as monotherapy in
those unable to tolerate UDCA. Accelerated approval
was based on a reduction in alkaline phosphatase
(ALP) levels. Seladelpar is the second PPAR agonist
to be approved in the US for this indication; elafibranor
(Iqirvo)...
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-5 doi:10.58347/tml.2025.1720d | Show Introduction Hide Introduction